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b-adrenergic receptors (b-ARs), prototypic G-
protein-coupled receptors (GPCRs), play a criti-
cal role in regulating numerous physiological
processes. The GPCR kinases (GRKs) curtail
G-protein signaling and target receptors for
internalization. Nitric oxide (NO) and/or S-nitro-
sothiols (SNOs) can prevent the loss of b-AR
signaling in vivo, but the molecular details are
unknown. Here we show in mice that SNOs
increase b-AR expression and prevent ago-
nist-stimulated receptor downregulation; and
in cells, SNOs decrease GRK2-mediated b-AR
phosphorylation and subsequent recruitment
of b-arrestin to the receptor, resulting in the
attenuation of receptor desensitization and in-
ternalization. In both cells and tissues, GRK2 is
S-nitrosylated by SNOs as well as by NO syn-
thases, and GRK2 S-nitrosylation increases fol-
lowing stimulation of multiple GPCRs with ago-
nists. Cys340 ofGRK2 is identified as a principal
locus of inhibition by S-nitrosylation. Our stud-
ies thus reveal a central molecular mechanism
through which GPCR signaling is regulated.
INTRODUCTION
G-protein-coupled receptors (GPCRs) comprise the larg-
est known family of cell-surface receptors and are funda-
mentally involved inmammalian physiology (Lefkowitz and
Shenoy, 2005; Pierce et al., 2002). This receptor super-family represents the largest single target for modern
drug therapy, and GPCR dysfunction/dysregulation is a
major contributor to the pathophysiology of disease. The
GRKs play an essential role in GPCR regulation by phos-
phorylating agonist-occupied receptors and promoting
their desensitization, internalization, and downregulation
(Lefkowitz and Shenoy, 2005; Pierce et al., 2002). b-ARs
are prototypical GPCRs, playing a critical role in the regu-
lation of cardiovascular (Rockman et al., 2002) and pulmo-
nary function (Johnson, 1998) as well as other physiolog-
ical processes, and the idea has been formalized that
b-AR dysfunction may be both a cause of cardiovascular
and respiratory impairment and a consequence of agonist
therapy (Insel, 1996). In particular, loss of b-AR responsiv-
ity is thought to be causally linked to both heart failure
(Lefkowitz et al., 2000) and asthma (Johnson, 1998) aswell
as to the morbidity and mortality associated with thera-
peutic uses of b agonists (Currie et al., 2006). Multiple lines
of evidence suggest that receptor desensitization and
downregulation represent important molecular mecha-
nisms contributing to b-AR dysfunction in the clinical
setting, and further point to a pathogenic role for GRKs,
particularly the GRK2 isotype (a.k.a. b-adrenergic recep-
tor kinase 1; Choi et al., 1997; Hata et al., 2004; Iaccarino
et al., 1998; Lefkowitz et al., 2000; Penn et al., 1998; Per-
rino et al., 2005; White et al., 2000). Thus, there is great
interest in elucidating the cellular mechanisms by which
GRKs are regulated, including GRK2 in particular.
It is well established that bioactive products of NO syn-
thases, principally nitric oxide (NO) and low-molecular-
weight S-nitrosothiols (SNOs), regulate a diverse array of
signal transduction pathways, acting in significant part
through the covalent modification (S-nitrosylation) of cys-
teine residues that are found at active or allosteric sites of
proteins (Hess et al., 2005). In a prototypic example of anCell 129, 511–522, May 4, 2007 ª2007 Elsevier Inc. 511
NO-signaling module, the activation of neuronal NMDA
receptors is coupled to the localized production of NO,
which S-nitrosylates both the receptor itself, downregulat-
ing receptor activity as well as associated regulatory (e.g.,
NSF) and effector (e.g., ras, dexras, GAPDH, and Parkin)
proteins that play roles in trafficking of receptors and in
transmitting the cellular signals (Chung et al., 2004; Fang
et al., 2000; Hara et al., 2005; Hess et al., 2005; Huang
et al., 2005; Jaffrey et al., 2001; Lipton et al., 1993). Al-
though the molecular details are less clear, mounting evi-
dence indicates that signaling through GPCRs might also
be regulated by S-nitrosylation. Exposure of cells and tis-
sues to nitrosylating agents has been shown to inhibit or
potentiate the signaling of multiple GPCRs (Hess et al.,
2005; Kokkola et al., 2005), and cysteine residues that
confer NO responsivity have been identified in the b2-AR
(Adam et al., 1999) and AT1 angiotensin receptors (Leclerc
et al., 2006). In cultured cells, protein SNOs increase fol-
lowing GPCR activation (Gow et al., 2002), and S-nitrosy-
lation that follows stimulation of b-ARs has been shown to
modulate both G-protein signaling and receptor internali-
zation: adenylate cyclase (Ostrom et al., 2004), the L-type
calcium channel (Sun et al., 2006), and dynamin (Wang
et al., 2006) have been identified as loci of NO regulation.
Interestingly, diminished responsiveness (tachyphy-
laxis) to b2-AR agonists, as assessed by either vasodila-
tion (Whalen et al., 2000) or airway relaxation (Que et al.,
2005), can be reversed by administration of SNOs (Que
et al., 2005; Whalen et al., 2000), and mice with a genetic
alteration that impairs breakdown of SNOs are protected
from tachyphylaxis (Que et al., 2005). Conversely, b2-AR
tachyphylaxis is enabled in vivo by the inhibition of NO
synthase (NOS; Whalen et al., 2000), which depletes en-
dogenous SNOs (Gow et al., 2002; Liu et al., 2004). On
the basis of these data and the knowledge that asthma
and heart failure are in fact characterized not only by los-
ses of b-AR responsivity (Currie et al., 2006; Insel, 1996;
Johnson, 1998; Lefkowitz et al., 2000) but also of NO bio-
activity (Gaston et al., 2006; Hare and Stamler, 2005), we
sought to investigate the molecular mechanism(s) by
which NO or SNO might preserve b-AR function.
RESULTS
NO/SNOs Modulate b-AR Function
and Homeostasis In Vivo
In light of previous findings showing that NO/SNOs pro-
tect against tachyphylaxis to b-agonists in the vasculature
(Whalen et al., 2000) and lungs (Que et al., 2005), we
sought to determine whether a similar effect could be ob-
served in the heart. Specifically, we examined the effect
of NOS inhibition on the inotropic response to sustained
high-dose infusions of the b-AR agonist, isoproterenol
(ISO), using a previously established model of tachyphy-
laxis (Matkovich et al., 2006). NOS inhibition with L-NG-
nitroarginine methyl ester (L-NAME; 50 nmol/g) was found
to markedly accelerate a decline in contractility during
maintained catecholamine (ISO) stimulation (dP/dtmax;512 Cell 129, 511–522, May 4, 2007 ª2007 Elsevier Inc.Figure 1A) without impairing basal contractility or initial
ISO-stimulated contractility (ISO-stimulated dP/dt was in
fact higher with L-NAME, reflecting an increase in mean
arterial pressure; Figure S1; Table S1). NOS-derived NO
bioactivity thus preserves b-AR signaling in the heart. As
an additional measure of NO/SNO’s effect on b-AR re-
sponsivity, we examined whether SNOs can modulate
b-AR expression in the heart; the b-AR is known to be
downregulated by prolonged infusion of ISO (Zhao and
Muntz, 1993). Notably, coinfusion of the endogenous
SNO, S-nitrosoglutathione (GSNO), completely prevented
the ISO-stimulated downregulation of the b-AR without
affecting basal b-AR expression (Figure 1B). To ascertain
whether endogenous SNOsmight similarly influence b-AR
Figure 1. Effect of Endogenous and Exogenous S-Nitroso-
thiols on b-AR Signaling and Expression In Vivo
(A) Decline in ISO-stimulated (20ng/g/min; continuous infusion) cardiac
contractility (dP/dtmax) over time inWTmice pretreatedwith either PBS
or L-NAME (50 nmol/g). Data (mean ± SEM) are expressed as change
from peak dP/dtmax (for absolute dP/dt values see Figure S1). n = 6
for each group, p < 0.001 by two-way ANOVA, and *p < 0.01 versus
PBS.
(B) b-AR density (Bmax; mean ± SEM) was measured (Rockman et al.,
1998) in membranes derived from hearts of mice infused continuously
with PBS, ISO (30mg/kg/day), GSNO (10mg/kg/day), or a combination
of ISO and GSNO for 7 days. n = 5, *p < 0.05 versus PBS or GSNO-
treated mice, and +p < 0.05 versus ISO-treated mice.
(C and D) Basal b-AR density (mean ± SEM) in membranes from heart
(C) and lungs (D) obtained from WT and GSNO reductase knockout
(GSNOR/) mice. n = 3, and *p < 0.05 versus WT.
Figure 2. CysNO Inhibits b-Arrestin As-
sociation with the b2-AR
(A) CysNO (10 mM; 5 min pretreatment)
markedly decreases ISO-stimulated (10 mM;
10 min) recruitment of b-arrestin2-GFP to the
plasma membrane of HEK293 cells (shown as
punctae; Barak et al., 1997) transiently over-
expressing the b2-AR. For clarity, magnified
confocal image shows punctate pattern of
b-arrestin at the membrane.
(B) Agonist-induced interaction between b-
arrestin and b2-AR and subsequent internaliza-
tion of the receptor in U2-OS cells coexpress-
ing both b2-AR-mCFP and b-arrestin2-mYFP.
b2-AR is localized to plasmalemma and b-
arrestin to cytosol prior to stimulation (top
row); under nonstimulated conditions, b2-AR:b-
arrestin do not interact as assayed by FRET
corrected for spectral overlap (FRETc). Ten
minutes after addition of 1 mM ISO (bottom
row), b-arrestin-mYFP has translocated to
plasmalemmal punctae, and b2-AR-mCFP has
internalized. Robust b2-AR:b-arrestin interac-
tion is detected by FRET at the plasma mem-
brane but not in vesicles containing internalized
receptor. Data are also displayed as an inten-
sity-modulated pseudocolor display, where
intensity corresponds to b2-AR-mCFP fluores-
cence, and color ranges from low FRET ratio
(blue) to high FRET ratio (red).
(C) Inhibition by CysNO of agonist-induced
b-arrestin translocation and b2-AR:b-arrestin
interaction. CysNO (50 mM pretreatment for
10 min followed by washout) visibly reduced
ISO-stimulated b-arrestin2-mYFP transloca-
tion (punctae on membrane) and b2-AR-
mCFP:b-arrestin2-mYFP (FRETc intensity).
Images are representative of four independent
experiments.homeostasis, we measured b-AR surface expression in
the hearts and lungs of wild-type (WT) mice as well as in
GSNO reductase null (GSNOR/) mice that are deficient
in the breakdown of GSNO (Liu et al., 2004). GSNOR/
mice exhibited significantly higher b-AR expression in
both the heart (Figure 1C) and lungs (Figure 1D) compared
to WT mice. These data, in addition to previously pub-
lished reports (Que et al., 2005; Whalen et al., 2000), dem-
onstrate that both b-AR signaling and cell-surface expres-
sion can be regulated in vivo by SNOs.
Effect of SNOs on Recruitment of b-Arrestin
to the b-AR
GRK-mediated phosphorylation of the agonist-stimulated
receptor constitutes a central locus of control over b-AR
signaling and internalization. Receptor phosphorylation
promotes the recruitment of b-arrestins to the receptor,
where they prevent further activation of heterotrimeric Gproteins, thereby desensitizing the receptor while promot-
ing clathrin-mediated receptor endocytosis (Pierce et al.,
2002). Desensitization and downregulation of b-ARs in the
heart, which is exemplified in Figures 1A and 1B, is in large
part mediated by GRK2 (Matkovich et al., 2006; Tilley and
Rockman, 2006). Inhibition of b-AR phosphorylation might
therefore explain a major part of the effect of SNOs, and
it should be noted in this regard that the effects elicited
by SNOs (Figure 1) are very similar to those reported for
GRK2-ct, an inhibitor of GRK2 (Koch et al., 1995; Rock-
man et al., 1998).
To begin to explore this possibility, we first expressed
GFP-labeled b-arrestin2 in HEK293 cells and examined
the effect of S-nitrosocysteine (CysNO), a cell-permeable
SNO (and endogenous byproduct of GSNO; Lipton et al.,
2001), on the ISO-induced recruitment of b-arrestin2 to the
b2-AR, which is highly dependent on GRK activity. As visu-
alized by confocal microscopy (Figure 2A), recruitment ofCell 129, 511–522, May 4, 2007 ª2007 Elsevier Inc. 513
Figure 3. Inhibition by SNOs of GRK-Dependent Functions
(A) Inhibitory effect of CysNO on ISO-stimulated b-arrestin recruitment. U2-OS cells expressing b2-AR-mCFP and b-arrestin2-mYFP were stimulated
with 1 mM ISO (with or without a 10 min pretreatment with 50 mMCysNO followed by washout as in Figures 2B and 2C), and the FRET ratio was fit to
a monoexponential curve.
(B) Quantification of b-arrestin binding and its inhibition by CysNO. The rate of ISO-stimulated FRET increase (kobs) was determined from curves fit as
in (A), providing an estimation of GRK function (Violin et al., 2006). n = 4, and *p < 0.001 by ANOVA.
(C) CysNO (50 mM; 10 min pretreatment followed by washout) decreases ISO-stimulated (10 mM; 30 s) association of endogenous b-
arrestins with stably expressed b2-AR in U2OS cells, as revealed by immunoprecipitation of crosslinked complexes. n = 3, and *p < 0.05 versus con-
trol. Grouping of images from within the same gel is indicated by dividing lines (white).
(D) CysNO inhibits whole-cell receptor phosphorylation. U2-OS cells stably expressing FLAG-b2-ARwere pretreatedwith either PBS or 50 mMCysNO
and stimulated with 10 mM ISO for 2 min. n = 3, and *p < 0.05 versus control.
(E and F) CysNO prevents b2-AR desensitization. U2-OS cells expressing the cAMP sensor ICUE2 were stimulated with 1 mM ISO with or without
a 5 min pretreatment with 1 nM ISO. The reduction in rate of cAMP accumulation resulting from ISO pretreatment is reported as percent desensiti-
zation. Addition of CysNO 10 min prior to the experiment (50 mM; followed by washout) inhibited desensitization (i.e., increased cAMP) versus control
(*p < 0.02; n = 5). CysNO (red) had no effect on ISO-stimulated (1 mM) cAMP accumulation in the absence of ISO pretreatment.
(G) CysNO inhibits b2-AR internalization. Internalization was measured by flow cytometry in U2-OS cells stably expressing FLAG-b2-AR after stimu-
lation with 10 mM ISO for 10 min. Pretreatment of cells with 50 mM CysNO was for 10 min. n = 6, and *p < 0.05 versus control.
Data in (B), (C), (D), (F) and (G) are means ± SEM.b-arrestin2 was markedly inhibited by pretreatment with
CysNO (1–10 mM). Additionally, in U2-OS cells we utilized
a fluorescent resonance energy transfer (FRET) assay,
which tracks the interaction between CFP-b2-AR and
YFP-b-arrestin2 as the latter is recruited to the plasma
membrane following ISO-stimulated, GRK2/3-dependent
phosphorylation of the b2-AR-mCFP (Violin et al., 2006).
Quantitation in U2-OS cells of the rate and amplitude of
ISO-stimulated b-arrestin association with the b2-AR may
thus provide an estimate, in real time, of the activity of the
closely related GRK isoforms GRK2 and GRK3, which
stands in opposition to HEK293 cells, where the b2-AR is
phosphorylated primarily by GRK6 (Violin et al., 2006). No-
tably, CysNO pretreatment (50 mM, followed by washout)
produced amarked decrease in the observed FRET signal
(FRETc; Figure 2B versus Figure 2C) and, accordingly, in514 Cell 129, 511–522, May 4, 2007 ª2007 Elsevier Inc.the measured rate (kobs) of ISO-stimulated recruitment of
b-arrestin2 to the b2-AR (Figures 3A and 3B), which is an
effect comparable to that recently reported with siRNA
for GRK2/3 in these cells (Violin et al., 2006). Confirmation
that CysNO inhibits ISO-stimulated recruitment to the
receptor of both endogenous b-arrestins (Figure 3C) and
YFP-b-arrestin2 (Figure S2) was obtained in crosslinking
studies. CysNO, like siRNA for GRK2/3 (Violin et al.,
2006), did not affect themaximum amount of b-arrestin re-
cruitment (Figure 3A); these findings are consistent with
emerging evidence that the b-AR may be regulated by
multiple GRKs and/or with the possibility that b-arrestin
binding to the b-AR can be induced by changes in recep-
tor conformation (consequent upon agonist stimulation)
that are independent of phosphorylation (Shenoy et al.,
2006; Violin et al., 2006).
Figure 4. Regulatory S-Nitrosylation of
GRK2
(A) Inhibition of whole-cell receptor phosphory-
lation by CysNO. WT, PKA, and Y326A b2-AR
phosphorylation in HEK293 cells treated with
10 mM CysNO. Mean ± SEM, n = 3. *p < 0.05
versus control.
(B) cGMP has no effect on whole-cell phos-
phorylation of the WT b2-AR. HEK293 cells
were treatedwith increasing doses of themem-
brane-permeable cGMP analog, 8-chlorophe-
nylthio-cGMP (for 10 min) and then stimulated
with ISO. Data show mean ± SEM, and n = 3.
(C and D) In vitro phosphorylation of either
purified b2-AR or rhodopsin (C) or peptide sub-
strate (D) by GRK2 is inhibited by S-nitroso-
thiols. Negative controls in (C) are without GRK2.
Grouping of images from within the same gel
is indicated by dividing lines (white). Data in
(C) are representative of three experiments
and, in (D), are the mean of two experiments
(error bars represent the range of the data).
(E) S-nitrosylation of GRK2 by GSNO and
CysNO (50 mM each), as measured by biotin
switch (representativeof twoexperiments), cor-
relates with the degree of GRK2 inhibition in (D).
(F)S-nitrosylation ofGRK2byCysNO (50mMfor
15min) yields1:1 SNO toGRK2 stoichiometry
(mean, n = 3) as quantified by photolysis chem-
iluminescence, where SNO is the difference ±
Hg (with reference to GSNO standard).SNOs Modulate Multiple GRK2-Dependent
Processes
In further support of these findings, we determined in U2-
OS cells that CysNO pretreatment (followed by washout)
decreased cellular responses that are dependent on
GRK2 activity: (1) CysNO decreased ISO-stimulated
whole-cell phosphorylation of the b2-AR (Figure 3D); (2)
CysNO reduced ISO-stimulated receptor desensitization
(Figures 3E and 3F), assayed using a FRET-based cAMP
reporter with which desensitization is measured as the ex-
tent to which prestimulation with ISO attenuates the rise
in cAMP induced by a subsequent ISO challenge (DiPilato
et al., 2004; Experimental Procedures). Thus, CysNO en-
hanced the rate of ISO-stimulated cAMP production in
cells that had been prestimulated with ISO (Figure 3E)
while having no effect on the initial ISO-stimulated in-
crease in cAMP, recapitulating the effects of siRNA for ei-
ther GRK2/3 or b-arrestin (data not shown); and (3) CysNO
decreased ISO-stimulated receptor internalization (Fig-
ure 3G) as quantified by flow cytometry.
S-Nitrosylation Inhibits GRK2-Mediated
Phosphorylation
HEK293 cells have long been used as a model system to
explore the molecular mechanisms of b-AR regulation
(Lefkowitz et al., 2002) and, more recently, to identify the
effects of NO on several classes of receptors (Huang
et al., 2005; Wang et al., 2006). Consistent with our results
in U2-OS cells, preincubation of HEK293 cells with CysNO(10 min) significantly inhibited agonist-induced whole-cell
phosphorylation of the b2-AR (Figure 4A). In addition,
CysNO inhibited the phosphorylation of a mutant b2-AR
from which PKA phosphorylation sites had been removed
(Figure 4A; Hausdorff et al., 1989), and, in cells overex-
pressing GRK2, CysNO inhibited the phosphorylation of
a Y326Amutant b2-AR that can only be phosphorylated by
overexpressed GRK (Ferguson et al., 1995; Figure 4A).
CysNO effects may be either cGMP-dependent or -inde-
pendent, with the latter mainly being elicited by S-nitro-
sylation (Hess et al., 2005). The cell-permeable cGMP
analog, 8-chlorophenylthio-cGMP, had no effect on ago-
nist-induced phosphorylation (Figure 4B). Collectively,
these data are consistent with the possibility that CysNO
may inhibit GRK2 activity through a cGMP-independent
mechanism.
To establish that SNOs can directly inhibit GRK2 by
S-nitrosylation, we incubated purified recombinant GRK2
with several substrates (b2-AR, rhodopsin, or synthetic
peptide) in the presence or absence of CysNO and as-
sayed for both phosphorylation of substrates and SNO
content of GRK2. CysNO caused a dose-dependent inhi-
bition of agonist-induced phosphorylation of both b2-AR
and rhodopsin (Figure 4C), and a direct effect on GRK2
was verified by pretreatment with CysNO (followed by de-
salting) prior to assay (Figure S3). In addition, GSNO or
CysNO inhibited phosphorylation of a synthetic, noncys-
teinyl peptide substrate (RRREEEEESAAA; Onorato et al.,
1991; Figure 4D) that is not reactive to NO. S-nitrosylationCell 129, 511–522, May 4, 2007 ª2007 Elsevier Inc. 515
of GRK2 was demonstrated in these experiments by
biotin-switch assay (Jaffrey et al., 2001), in which the
Cys-bound NO (S-NO) is removed with ascorbate and
replaced with biotin to enable affinity purification and
quantification (see Supplemental Data for a complete
description; Figure 4E), and the amount of S-nitrosylation
was shown to be proportional to the degree of GRK2
inhibition. Precise quantification of S-nitrosylated GRK2
(SNO-GRK2), as measured by photolysis chemilumines-
cence, showed that the SNO to GRK2 stoichiometry
was 1:1 (Figure 4F) under conditions where substrate
phosphorylation was inhibited by >80% (Figures 4C
and 4D).
Endogenous GRK2 S-Nitrosylation
In support of the relevance of these data to the physiolog-
ical situation, we determined that exposure of HEK293
cells expressing GRK2 to CysNO resulted in the in situ
S-nitrosylation of GRK2 (vide infra) and that GRK2 was
constitutively S-nitrosylated in HEK293 cells that stably
express either nNOS (HEK-nNOS) or eNOS (HEK-eNOS;
Figure 5A), as measured by both biotin switch (Figure 5A)
andphotolysis-chemiluminescence (not shown). The iden-
tification of endogenous SNO in the biotin-switch assay
was validated by the elimination of (ascorbate-dependent)
signals by UV irradiation applied prior to assay (which
cleaves the S-NO bond; Stamler et al., 1992; Figure 5A).
Similarly, GRK2 was found to be endogenously S-nitrosy-
lated in cultured human umbilical vein endothelial cells
(HUVEC), and, moreover, the activation (by ATP, bradyki-
nin, and isoproterenol) of multiple endogenously ex-
pressed GPCRs, which are known to be coupled to
eNOS in these cells (Ferro et al., 1999; Gosink and Fors-
berg, 1993), led to an increase in GRK2 S-nitrosylation
(Figure 5B). Additionally, we analyzed the S-nitrosylation
state of native GRK2 in mouse tissues: S-nitrosylated
GRK2was readily detected at basal conditions in the lungs
of WT mice, whereas the levels were significantly de-
pressed in eNOS/ mice (Figure 5C). Conversely, SNO-
GRK2 levels were greater in the lungs of GSNOR/ mice
than in WT mice (Figure 5D); tissue levels of SNO-GRK2
(Figure 5D) thus paralleled changes in basal b-AR expres-
sion (Figure 1D).
Mapping the Site(s) of S-Nitrosylation in GRK2
We developed several complementary strategies to map
the site(s) of S-nitrosylation among the 15 cysteines of
GRK2. First, SNO-GRK2 was subjected to limited proteol-
ysis followed by the biotin-switch assay, resulting in
cleavage of full-length GRK2 into smaller biotinylated
fragments (Figure 6A). Sequencing by MALDI-TOF/TOF
mass spectrometry showed that the S-nitrosylation was
mostly identified with a 50 kDa N-terminal fragment,
which spanned the catalytic domain and contained 12
cysteines (data not shown). To further pinpoint the sites
of S-nitrosylation contained within the N-terminal frag-
ment, SNOs in GRK2 were replaced with biotin (biotin
switch), and peptides generated by trypsinization were516 Cell 129, 511–522, May 4, 2007 ª2007 Elsevier Inc.purified by avidin chromatography and analyzed by ESI-
MS/MS. Six biotinylated cysteine-containing peptides,
corresponding to sites of S-nitrosylation, were identified
(Figures 6B and 6C), including two Cys within the catalytic
domain (Cys340 and Cys439). Although the relative abun-
dance of each peptide could not be determined with this
Figure 5. Dynamic S-Nitrosylation of GRK2 by Endogenous
NO/SNO in Cells and Tissues
(A) GRK2 is constitutively S-nitrosylated in both HEK-nNOS and HEK-
eNOS cells. SNO signal (ascorbate-dependent biotin labeling) is elim-
inated by UV pretreatment of cell lysates (data are representative of
three experiments).
(B) Dynamic S-nitrosylation of endogenous GRK2 in endothelial cells.
Endothelial cells were treated with 5 mM ATP, 100 nM bradykinin, or
10 mM ISO for 5 min. ATP: n = 5, *p < 0.001 versus control (CTL);
bradykinin: n = 2, average; ISO: n = 3, **p < 0.05 versus control. Rep-
resentative biotin-switch blots for S-nitrosylated GRK2 are shown.
Grouping of images from within the same gel here and in (C) is indi-
cated by dividing lines (white).
(C and D) Constitutive S-nitrosylation of GRK2 in mouse lungs. SNO-
GRK2 in lungs of WT versus eNOS/ (C) and GSNOR/ (D) mice
was measured by biotin-switch assay; total GRK2 levels are un-
changed between groups. n = 3, and *p < 0.05 versus WT. Represen-
tative blots show S-nitrosylated and total GRK2.
Data in (B), (C), and (D) are mean ± SEM.
Figure 6. Identification of S-Nitrosylation
Sites in GRK2
(A) Initial mapping of SNO sites. Limited prote-
olysis (for the indicated times) of CysNO-
treated GRK2 followed by the biotin-switch
assay reveals biotin incorporation into N- and
C-terminal protein fragments (arrows). Data
are representative of three independent exper-
iments.
(B) SNO-containing peptides identified by ESI-
MS/MS. Biotinylated cysteines (C*; produced
by biotin switch; see Experimental Procedures)
represent sites of S-nitrosylation. Target cyste-
ines are located within the RH (regulator of G-
protein-signaling homology), Catalytic, and PH
(pleckstrin homology) domains.
(C) Representative ESI-MS/MS spectrum de-
rived from S-nitrosylated GRK2. SNO-GRK2
was subjected to a biotin switch, followed by
trypsinization and purification of biotinylated
peptides by avidin chromatography. The tryp-
tic peptide containing Cys340 is identified;
the peptide sequence is shown in the inset. La-
bels are as follows: b-ions (green), y-ions (red),
and internal acyl fragments (blue).
(D) GRK2 isS-nitrosylated at Cys340 byCysNO
(50 mM; 5 min). HEK cells were transfected with
WT or C340S GRK2. Grouping of images from
within the same gel is indicated by a dividing
line.
(E) S-nitrosylation of GRK2 at Cys340 by en-
dogenously derived NO. HEK-nNOS cells were
transfected with WT or C340S GRK2.
(F) ISO-stimulated (10 mM; 5 min) S-nitrosyla-
tion of GRK2 at Cys340. HUVEC cells were
transfected with WT or C340S GRK2 (Data
are mean ± SEM).
S-nitrosylation in (D), (E), and (F) was measured
by biotin switch. Images are representative of
three independent experiments.approach, quantitative analysis by photolysis chemilumi-
nescence suggested that most NO in fact resided with
one or few peptides (SNO:GRK2 z1), and it was noted
that Cys340 conforms to an acid-base motif (Greco
et al., 2006; Stamler et al., 1997) that is a characteristic
site of S-nitrosylation by GSNO or CysNO (Greco et al.,
2006; Hess et al., 2005). Notably in HEK293 cells overex-
pressing GRK2, mutation of C340 to serine (C340S)
greatly attenuated S-nitrosylation by exogenous CysNO
(Figure 6D), as well as by NO derived from nNOS (Fig-
ure 6E). Moreover, in HUVEC cells, robust agonist-depen-
dent S-nitrosylation of GRK2 was eliminated by C340
mutation (Figure 6F). While these data do not exclude
NO effects on additional Cys, they point strongly to
Cys340 as a primary regulatory site.
Identification of Cys340 as a Site of Regulatory
S-Nitrosylation
We examined the effect of CysNO on phosphorylation of
the Y326A b2-AR by WT C340S or C439S GRK2 proteins
expressed in HEK293 cells (Y326A b2-AR was employedbecause it can only be phosphorylated by overexpressed
GRKs; Figure 7A). Using a b2-AR antibody specific forGRK
phosphorylation sites (pSer355,356; Tran et al., 2004), we
determined that CysNO inhibited b2-AR phosphorylation
by eitherWT or C439SGRK2 but had no effect on receptor
phosphorylation by C340S GRK2, thus identifying Cys340
with CysNO responsivity (Figure 7B). Further, the effects
of CysNO on b2-AR phosphorylation by GRK2 (WT and
C340S) translated directly to an effect on receptor inter-
nalization (Figure 7C): HEK293 cells stably expressing
b2-AR and transiently transfected with WT GRK2 showed
a significant decrease in agonist-stimulated b2-AR inter-
nalization after CysNO pretreatment, whereas cells ex-
pressing C340S GRK2 actually showed a slight increase
in agonist stimulated b2-AR internalization (Figure 7C).
Likewise, in HEK293 cells stably expressing NOS, b2-AR
internalization promoted byWTGRK2was significantly di-
minished relative to that by C340S GRK2 (Figure 7D), pre-
sumably reflecting the much higher level of endogenously
S-nitrosylated WT GRK2 versus C340S GRK2 (Figure 6E).
Notably, the effects of both exogenous CysNO (FiguresCell 129, 511–522, May 4, 2007 ª2007 Elsevier Inc. 517
Figure 7. Identification of Regulatory Locus of S-Nitrosyla-
tion in GRK2
(A) Phosphorylation of the Y326A b2-AR requires cotransfection of
GRK2. HEK cells transfected with Y326A b2-AR were or were not co-
transfected with WT GRK2 and stimulated with agonist (epinephrine).
Western blot is representative of three independent experiments.
(B) CysNO inhibits phosphorylation of the b2-AR by WT and C439S
GRK2 but not by C340S GRK2. Agonist-stimulated phosphorylation
of the Y326A b2-AR (at Ser355, Ser356) by WT, C439S GRK2, or
C340S GRK2 in the presence or absence of CysNO (50 mM) is shown.
b2-AR phosphorylation was determined in HEK293 cells 20 min after
addition of epinephrine (1 mM). Data are representative of three inde-
pendent experiments. Within gel grouping of images is indicated by
dividing lines (white).
(C) Inhibition by CysNO of GRK2-dependent receptor internalization in
cells expressingWTGRK2 (WT) but not C340S GRK2 (C340S). Recep-
tor internalization (mean ± SEM) was quantified by flow cytometry in
HEK293 cells stably coexpressing FLAG-b2-AR after stimulation with
10 mM ISO for 20 min (as in C). n = 8, *p < 0.001 CysNO versus control,
WT GRK2-transfected cells, and **p < 0.05 CysNO versus control,
C340S GRK2-transfected cells; yp < 0.001 WT GRK2 plus CysNO ver-
sus C340S GRK2 plus CysNO. The relative expression of WT and
C340S GRK2 were equivalent. UT indicates untransfected cells at
20 min post ISO.
(D) Inhibition of GRK2-dependent receptor internalization by endoge-
nous NO is dependent on Cys340. Receptor internalization (mean ±
SEM) was quantified in HEK-eNOS cells transiently overexpressing
the b2-AR and either WT or C340S GRK2 after stimulation with
10 mM ISO for 5 min. C340S GRK2 expression was equivalent to
WT. n = 12, and *p < 0.001, C340S GRK2 versus WT GRK2.
(E) Activation loops of GRK2 and cyclic AMP-dependent protein kinase
(PKA), a prototypic AGC kinase. In PKA (PDB:1CMK), the phosphate of
phosphoThr197 (within the activation loop [light blue]) maintains an
electrostatic interaction with an Arg165 (of the catalytic loop [green])
that is required for ATP binding and phosphoryltransfer. The catalytic518 Cell 129, 511–522, May 4, 2007 ª2007 Elsevier Inc.3A, 3E, and 7C) and endogenous NO (Figure 7D) on
GRK2-dependent receptor internalization were most
readily demonstrated at early time points following ISO
stimulation (5–10 min versus 20–30 min), corresponding
to the exponential phase of b-arrestin recruitment (Fig-
ure 3A) and receptor internalization (Wang et al., 2006),
during which inhibition of b-arrestin recruitment by NO is
most pronounced (Figure 3A).
DISCUSSION
A Novel Regulatory Locus
The dampening of G-protein signaling and coordinate tar-
geting of receptors for internalization that occurs following
their stimulation by agonists is a central aspect of GPCR
regulation. In the prototypic case of the b-AR, the uncou-
pling of receptor from cognate G protein (Gs) suppresses
second messenger signaling (cAMP/PKA) and promotes
the b-arrestin-dependent recycling of receptors via the
trafficking machinery (Lefkowitz and Shenoy, 2005; Pierce
et al., 2002). b-arrestin binding to the b-AR is initiated by
GRKs, and most of our understanding of these phosphor-
ylation events is based on studies of GRK2. Excessive
GRK2 activity can lead to downregulation of receptors
that impairs second messenger signaling (Lefkowitz and
Shenoy, 2005; Pierce et al., 2002). The question arises
as to how GPCR phosphorylation events are regulated
to prevent unwanted receptor desensitization and down-
regulation. Here we establish that agonist-induced phos-
phorylation of the b-AR by GRK2, as well as the sub-
sequent recruitment of b-arrestin to curtail signaling
(desensitization) and promote receptor internalization,
are regulated by S-nitrosylation. GRK2 S-nitrosylation
puts a brake on GRK2 activity that potentiates second
messenger (cAMP) signaling and mitigates agonist-
dependent receptor internalization.
Our data show that Cys340 is a primary target of endog-
enously derived and exogenously supplied NO or SNO,
and that S-nitrosylation at this site inhibits GRK2 activity.
Inhibitory S-nitrosylation of GRK2 provides a potential ex-
planation for prior reports that NO/SNO can facilitate
GPCR signaling and prevent tachyphylaxis in vivo (Que
et al., 2005; Whalen et al., 2000). It is interesting to note
that Cys340 (and surrounding residues that conform to
a canonical S-nitrosylation motif (Greco et al., 2006;
Hess et al., 2005; Stamler et al., 1997), is located on a b-
sheet flanking the ‘‘activation loop’’ of the catalytic domain
(see Figure 7F); in PKA and other AGC kinases, the loop
contains a phospho-Thr residue (not present in GRK2)
that is required for kinase activity through an interaction
with Arg165 (PKA numbering; Adams et al., 1995). S-nitro-
sylation of Cys340 may thus perturb the structure of the
activation loop or orientation of Arg316. Primary sequence
analysis indicates that Cys340 is conserved in the
and activation loop structures are preserved in GRK2 (PDB:1OMW),
where Arg316 might be stabilized through interactions with Tyr368
and Cys340.
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kinases, suggesting that the widely distributed GRKs 2
and 3 are subject to a unique mode of regulation. It is im-
portant to note that GRK2 has additional functions, and
mass spectrometric and cellular results (Figure 6B and
6F, and data not shown) have indicated that GRK2S-nitro-
sylation by exogenous NO donors and endogenously gen-
erated NO may, under the appropriate conditions, be in-
duced at additional Cys residues. Thus, there is the
possibility of as yet undiscovered, distinct effects on
GRK activity and function by nitrosylation at these addi-
tional sites.
Confluence of NO and GPCR Systems
nNOS, eNOS (and to some degree iNOS) are widely asso-
ciated with plasma membranes, overlapping the localiza-
tion of GPCRs (Brenman et al., 1996; Dudzinski et al.,
2006; Felley-Bosco et al., 2000; Fulton et al., 2001).
NOSs not only bind directly to certain GPCRs (Ju et al.,
1998), but also co-segregate with the receptors in signal-
ing modules (Prabhakar et al., 1998) through interactions
with caveolin (Dudzinski et al., 2006; Felley-Bosco et al.,
2000; Garcia-Cardena et al., 1996), PSD-95 (Brenman
et al., 1996; Hess et al., 2005; Hu et al., 2000), and other
membrane proteins (Brenman et al., 1996; Cao et al.,
2001; Wang et al., 2006). Stimulation of multiple classes
of GPCRs, including the b2-AR, P2Y receptor, cholinergic
receptor and bradykinin receptor, induces Ca2+ influx and
activation of eNOS (Dudzinski et al., 2006; Ferro et al.,
1999; Kaiser et al., 2002). In addition, eNOS can be acti-
vated downstream of b2-AR by PKA- and Akt-dependent
mechanisms (Ferro et al., 1999). Interestingly, eNOS
may associate with GRK2 through a mutual interaction
with several elements, including Akt, calmodulin, caveolin
and Hsp90 (Hansen et al., 2006; Liu et al., 2005). NO pro-
duction within the confines of protein complexes allows
for the spatiotemporal exactitude of S-nitrosylation requi-
site in signal propagation (Hess et al., 2005; Stamler et al.,
2001). However, while multiple signaling elements are
known to be S-nitrosylated (or denitrosylated) down-
stream of activated GPCRs, including adenylate cyclase,
L-type calcium channels and TRP channels (Hess et al.,
2005; Ostrom et al., 2004; Sun et al., 2006; Yoshida
et al., 2006), the finding that NO can regulate b-AR phos-
phorylation provides a unique locus through which S-
nitrosylation exerts conjoint control over receptor signal-
ing and internalization.
It has been previously reported that NO produced upon
b2-AR stimulation activates the largeGTPase dynamin and
thereby facilitates receptor internalization (Wang et al.,
2006). Opposing effects of S-nitrosylation on GRK2-medi-
ated receptor desensitization () and dynamin-mediated
receptor internalization (+) (Wang et al., 2006), suggest
that S-nitrosylation of those components is differentially
regulated, perhaps as a result of their association with dif-
ferent pools of NOS (unlike the binding of GRK2 with
eNOS-associated proteins, dynamin associates directly
with eNOS; Wang et al., 2006). Thus NO derived from dif-ferent populations of NOSmay operate in concert to atten-
uate desensitization and internalization on the one hand
while facilitating receptor trafficking on theother. Taken to-
gether, these and other findings reveal multiple targets of
NO/ SNO, which comprise both constitutively and dynam-
ically S-nitrosylated proteins that may serve to control
GPCR-regulated functions both under basal conditions
and following stimulation by agonists.
Perspective
On the basis of our findings, we suggest that the dynamic
S-nitrosylation of GRK2, observed in cells and tissues, ex-
erts an inhibitory influence on GPCR phosphorylation that
functions to prevent receptor desensitization and downre-
gulation. Diseases such as heart failure and asthma are
characterized by both a deficiency of NO bioactivity and
dysfunction of b-AR signaling, including downregulation
and desensitization of receptors (Currie et al., 2006; Gas-
ton et al., 2006; Hare and Stamler, 2005; Insel, 1996; John-
son, 1998; Lefkowitz et al., 2000), and much evidence
points to GRK2 as a culprit (Choi et al., 1997; Hata et al.,
2004; Iaccarino et al., 1998; Lefkowitz et al., 2000; Penn
et al., 1998; Perrino et al., 2005; White et al., 2000). Fur-
ther, b-AR desensitization can be recapitulated in healthy
tissues by inhibition of NOS, and function is restored
in vivo by infusion of SNOs (Whalen et al., 2000; Figure 1),
and we now also show that both endogenous and exoge-
nous SNOs can mitigate b-AR desensitization and down-
regulation. Taken together, these findings support the idea
that inhibition of GRK2 by supplementation of SNOsmight
restore receptor signaling in disease states and thus pro-
vide a novel therapeutic modality. More generally, our
data identify a novel role for NO in regulation of GPCR
function and point to the possibility that deficiencies in
NO bioactivity, which characterize many disease states,
including hypertension, diabetes, atherosclerosis, cystic
fibrosis, neurodegenerative conditions, and aging, may
entail dysregulation of GPCR-based signaling.
EXPERIMENTAL PROCEDURES
Detailed Experimental Procedures with References are included in the
Supplemental Data. An abbreviated summary is provided.
Hemodynamic Studies
Isoflurane-anesthetized mice underwent cardiac catheterization. A
Millar catheter was used to measure hemodynamics, and drugs were
infused through the jugular vein.
GSNO Infusion and Radioligand Binding
Mice were implanted with micro-osmotic pumps (Alzet) for the chronic
administration of drugs. Heart and lung membranes were prepared,
and 125I-cyanopindolol binding was performed.
b-Arrestin Recruitment
HEK293 and U2-osteosarcoma (U2-OS) cells were transfected with
either the FLAG-b2-AR and b-arrestin2-GFP or the b2-AR-mCFP and
b-arrestin2-mYFP, and agonist-stimulated increases in the association
of b-arrestin2 with the receptor were measured using confocal
microscopy, FRET, or chemical crosslinking (coimmunoprecipitation)
methodologies.
Real-Time cAMP Assay
U2-OS cells were stably transfected with an enhanced version of the
cAMP reporter ICUE (DiPilato et al., 2004), which was kindly provided
by Jin Zhang. b-ARdesensitizationwasmeasured using a restimulation
protocol.
Phosphorylation Assays
Whole-cell phosphorylation assays were performed using both 32P
orthophosphate labeling and an anti-pSer(355,356) b2-AR antibody.
In vitro phosphorylation assays were performed with purified bovine
GRK2 and various substrates (purified b2-AR, rhodopsin, and a syn-
thetic peptide).
Receptor Internalization
Agonist-induced internalization of Flag-b2-AR was determined by flow
cytometry.
Identification of SNO-GRK2
S-nitrosylatedGRK2 frommouse lungs,mammalian cells, and sf9 cells
was measured using a number of established techniques, including
photolysis-chemiluminescence, biotin switch, and mass spectrome-
try. The sites of GRK2 S-nitrosylation were identified by MALDI-TOF/
TOF and LC-MS/MS mass spectrometry (coupled with biotin switch).
Statistical Analysis
Cardiac contractility in mice and effects of CysNO treatment on b-
arrestin binding to the b2-AR over time were analyzed by ANOVA
(with post hoc Bonferonni). Other comparisons were made with the
unpaired Student’s t test.
Supplemental Data
Supplemental Data include one table, four figures, Experimental Pro-
cedures, and References and can be found with this article online at
http://www.cell.com/cgi/content/full/129/3/511/DC1/.
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